Eckert & Ziegler and AtomVie Global Radiopharma have entered a worldwide supply agreement in which Eckert & Ziegler will provide non-carrier-added lutetium-177 (Lu-177) chloride (Theralugand) to support AtomVie’s manufacturing capabilities.
The collaboration covers both early and late-stage development and extends to programs around the world. Through this partnership, AtomVie secures access to Theralugand, which will spur more development of Lu-177-based radiopharmaceuticals in their facility.
The companies noted that the flexibility of the agreement makes it possible to respond to the needs of pharmaceutical partners at different stages of radiopharmaceutical development and commercialization while addressing regulatory requirements worldwide.
AtomVie’s new facility is set to open later this year in Hamilton, Ontario, Canada.